James Christopher Edgemond | United Therapeutics Corp. |
Martine A. Rothblatt | United Therapeutics Corp. |
Michael Benkowitz | United Therapeutics Corp. |
Terence Flynn | Goldman Sachs & Co. LLC |
Geoff Meacham | Barclays Capital, Inc. |
Hartaj Singh | Oppenheimer & Co., Inc. |
Liana Moussatos | Wedbush Securities, Inc. |
Good morning and welcome to the United Therapeutics Corporation First Quarter 2013 Earnings Call. My name is Ashley, and I will be your conference operator today. All participants will be in a listen-only mode until the question-and-answer session of this earnings call. After the company's remarks, there will be a question-and-answer session. I would now like to turn the conference over to James Edgemond, Chief Financial Officer of United Therapeutics.